Literature DB >> 32334373

Bushenhuoxue formula promotes osteogenic differentiation of growth plate chondrocytes through β-catenin-dependent manner during osteoporosis.

Chenjie Xia1, Zhen Zou2, Liang Fang2, Qinwen Ge2, Peng Zhang2, Huihui Xu2, Rui Xu2, Zhenyu Shi2, Houfu Lin2, Xinyi Ding2, Luwei Xiao3, Peijian Tong4, Ping-Er Wang5, Hongting Jin6.   

Abstract

BACKGROUND: Bushenhuoxue formula (BSHXF) has shown excellent clinical effects on the treatment of osteoporosis in China. The aim of this study is to determine the anti-osteoporosis effects and precise molecular mechanisms of BSHXF on mouse models.
METHODS: Ten-week-old female C57BL/6 J mice were subjected to ovariectomy and provided a daily treatment of BSHXF. At 8 weeks post-surgery, the femurs were harvested for tissue analyses including μCT, histology, qRT-PCR and immunohistochemical (IHC) staining of β-catenin, ALP and FABP4. To investigate the role of β-catenin in the anti-osteoporosis effects of BSHXF, relative experiments mentioned above were performed in β-catenin conditional knockout mice.
RESULTS: Ovariectomized (OVX) mice presented severe bone loss and excessive fat accumulation in the chondro-osseous junction underneath the growth plate, with decreased expression of ALP and increased expression of FABP4. BSHXF significantly recovered the OVX-induced abnormal osteogenesis and adipogenesis with the activation of β-catenin in growth plate chondrocytes. Further, we generated growth plate chondrocyte-specific β-catenin knockout (β-cateninGli1ER) mice that exhibited bone loss and fat accumulation in the chondro-osseous junction, similar to the OVX mice. However, BSHXF failed to rescue the osteoporosis-like phenotype in β-cateninGli1ER mice, indicating the anti-osteoporosis effects of BSHXF act mainly through β-catenin signaling. No significant restoration of ALP and FABP4 was observed in β-cateninGli1ER mice after the treatment of BSHXF.
CONCLUSIONS: BSHXF attenuates osteoporosis by promoting osteogenic differentiation of growth plate chondrocytes mainly in β-catenin-dependent manner. BSHXF is considered as a new candidate for the treatment of osteoporosis.
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Bushenhuoxue formula; Cell differentiation; Osteoporosis; β-catenin

Year:  2020        PMID: 32334373     DOI: 10.1016/j.biopha.2020.110170

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

1.  Integration of Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanisms of Zhuanggu Busui Formula Against Osteoporosis.

Authors:  Huihao Zhang; Chengcong Zhou; Zhiguo Zhang; Sai Yao; Yishan Bian; Fangda Fu; Huan Luo; Yan Li; Shuxin Yan; Yuying Ge; Yuying Chen; Kunyu Zhan; Ming Yue; Weibin Du; Kun Tian; Hongting Jin; Xiaofeng Li; Peijian Tong; Hongfeng Ruan; Chengliang Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-28       Impact factor: 5.555

2.  Elucidation of the Underlying Mechanism of Gujian Oral Liquid Acting on Osteoarthritis through Network Pharmacology, Molecular Docking, and Experiment.

Authors:  Congzi Wu; Qinwen Ge; Zhenyu Shi; Jun Ying; Qi Sun; Shanxing Zhang; Jiali Chen; Pinger Wang; Wenhua Yuan; Songfeng Hu; Hongting Jin; Peijian Tong
Journal:  Biomed Res Int       Date:  2022-07-28       Impact factor: 3.246

3.  Effectiveness of Yushen Hezhi therapy for postmenopausal osteoporosis: An overview of systematic reviews of randomized controlled trials.

Authors:  Jinlong Zhao; Xiao Xiao; Guanghui Zhou; Nanjun Xu; Jun Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-26       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.